Hi Cars..Nice hearing from you. I was never enamored with the prospects of R1...too premature and too weak via "N". I also realize that between this company and the FDA, nothing ever gets done in an expedient manner. On top of that, there was really NO efficacy parameters that were anticipated in this trial, simply POC and safety with a low powered p2 like trial ( at best). R1 results have only part of the blame for the floundering pps. What about nine years of all the other bead data and pending products that have not come to fruition. Many investors have lost their patience and confidence in management, and in fact, the technology itself!
News 
Market Data 
Discover 
